(Prostate Cancer) Is PARP Inhibitor Rucaparib Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On August 14, 2020, Wassim Abida published results in the Journal of Clinical Oncology from the TRITON2 Phase 2 clinical trial evaluating the efficacy and safety of the PARP inhibitor Rucaparib in patients with BRCA1/BRCA2 gene mutation-positive, metastatic castration-resistant prostate cancer.
The TRITON2 Phase 2 trial enrolled 115 previously treated patients with BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer, who received Rucaparib monotherapy twice daily. The primary endpoints were objective response rate (ORR) and PSA response rate.
Approximately 12% of metastatic castration-resistant prostate cancer patients carry BRCA1 or BRCA2 gene mutations. These mutations increase the risk of prostate cancer development and metastasis. Because PARP inhibitors can suppress homologous recombination repair defects and DNA damage responses caused by BRCA1/BRCA2 mutations, they were expected to benefit this patient population.
Results:
- Primary endpoint ORR (IRC-assessed): 43.5%
- Primary endpoint ORR (investigator-assessed): 50.8%
- PSA response rate: 54.8%
Conclusion: Based on the TRITON2 trial results, Wassim Abida concluded that Rucaparib demonstrated meaningful anti-tumor activity in BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer patients, with a safety profile consistent with previously known adverse event data from other clinical trials.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Translation materials are for reference only. Please consult your healthcare provider for medical decisions.
Source: Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Aug 14; JCO2001035. doi: 10.1200/JCO.20.01035.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4